Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant DNA in Plasma of Lung Cancer Patients: Potential for Monitoring Response to Therapy

1 Jun 2004

Abstract excerpt

The hypothesis tested was that mutant tumor DNA shed into plasma would show predictive value for monitoring response to therapy in non-small cell lung carcinoma patients. Pretreatment plasma specimens from 25 patients on a phase I trial were evaluated, 12 with paired posttreatment specimens, and 138 patients on the Southwest Oncology Group S0003 trial, 38 with paired posttreatment specimens, for the presence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15251940
DOI: 10.1196/annals.1318.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Mutant DNA in Plasma of Lung Cancer Patients: Potential for Monitoring Response to TherapyPMID 15251940Read ↗

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients.Semantic proximity Read ↗

Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.Semantic proximity Read ↗

Detecting lung cancer in plasma with the use of multiple genetic markers.Semantic proximity Read ↗

Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.Semantic proximity Read ↗

Comparison of plasma to tissue DNA mutations in surgical patients with non–small cell lung cancerSemantic proximity Read ↗

Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance.Semantic proximity Read ↗

Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?Semantic proximity Read ↗

K-ras mutation in sputum of patients with or without lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.